Are glucagon-like peptide-1 (GLP-1) receptor agonists useful in treating Parkinson’s disease (PD)? Does the clinical trial with lixisenatide add anything?

Lixisenatide improved motor scores in Parkinson's disease patients under 60 years old after 12 months of treatment.

• The primary endpoint of motor changes was measured using the MDS-UPDRS part 3 scale.
• Statistical analysis showed a significant difference in motor scores between lixisenatide and placebo, but the clinical significance was not reached.
• Post hoc analysis indicated that younger patients (<60 years) experienced greater improvement in motor scores compared to older patients (≥60 years).
• No significant changes were observed in secondary or exploratory non-motor endpoints.
• The effects of lixisenatide on motor function may require long-term treatment to be clinically meaningful.

AI simplified